Skip to main content

Table 2 Prognostic factors for overall survival and recurrence-free survival

From: Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis

CharacteristicsOverall survivalRecurrence-free survival
UnivariateMultivariate analysisUnivariateMultivariate analysis
P valueHR95%CIP valueP valueHR95%CIP value
Age (year), (≤ 55 vs. > 55)0.477   0.786   
Gender (male vs. female)0.785   0.479   
Tumor location
 Left-sided vs. right-sided0.575   0.029*0.6590.478–0.9100.011*
Primary tumor characteristics
 T stage (T3/T4 vs. T1/T2)0.201   0.219   
 N stage (N1/N2 vs. N0)0.001*1.6001.155–2.2160.005*0.003*1.5331.159–2.0290.003*
 Tumor size (cm), (> 4 vs. ≤ 4)0.254   0.628   
 Postoperative chemotherapy (yes vs. no)0.501   0.018*1.4170.944–2.2170.093
CRLM characteristics
 Presentation of CRLM (synchronous vs. asynchronous)0.766   0.190   
 Preoperative chemotherapy (yes vs. no)< 0.001*1.2790.898–1.8220.1720.001*1.3550.975–1.8840.070
 CEA (μg/L), (> 200 vs. ≤ 200)0.020*1.1660.560–2.4280.6810.056   
 CA19-9 (kU/L), (> 35 vs. ≤ 35)0.015*1.2850.854–1.9330.2290.748   
 Tumor size (cm), (> 5 vs. ≤ 5)0.001*1.9231.298–2.8490.001*0.315   
 Tumor number (multiple vs. single)< 0.001*1.4460.988–2.1170.058<0.001*1.2440.907–1.7060.176
 Operative factors (with ablation vs. resection only)< 0.001*1.7231.129–2.6300.012< 0.001*1.7931.253–2.5660.001*
 R0 resection (no vs. yes)< 0.001*1.9981.424–2.804< 0.001*    
 Postoperative chemotherapy (yes vs. no)0.057   0.319   
  1. HR hazard ratio, CI confidence interval, T stage tumor stage, N stage node stage, CRLM colorectal liver metastases, CEA carcinoembryonic antigen, CA 19-9 carbohydrate antigen 19-9, R0 resection hepatectomy on patients with clear histological margins
  2. *P < 0.05